Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Sponsor: RedHill Biopharma Limited
This observational or N/A phase trial investigates Cholangiocarcinoma and Cholangiocarcinoma Non-resectable and is currently ongoing. RedHill Biopharma Limited leads this study, which shows 11 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
No Longer Available
Status: Available → No Longer Available
-
Sep 2024 — Apr 2025 [monthly]
Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
Apr 2022 — Jul 2024 [monthly]
Available
-
Apr 2021 — Apr 2022 [monthly]
Available
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Available
-
Feb 2020 — Jan 2021 [monthly]
Available
-
Dec 2018 — Feb 2020 [monthly]
Available
-
Jun 2018 — Dec 2018 [monthly]
Available
-
Apr 2018 — Jun 2018 [monthly]
Available
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.